The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Conversation with The Cancer LetterReal-world Evidence

Here’s something for the Bidens and ARPA-H to do: Build a national, federated ecosystem for digital health, MITRE proposes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

As American life returns to a semblance of normalcy, it may be time for President Biden’s administration to prioritize building a national digital health infrastructure.

Here’s a game plan for doing this rapidly:

On May 18, MITRE, a public interest non-profit that operates seven Federally Funded Research and Development Centers, published a draft national strategy for digital health. The plan encompasses six goals, which experts say could yield public health benefits on a national scale within months of implementation.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

YOU MAY BE INTERESTED IN

Podcast

Jonathan Mahler on his front-page story in the NYT Magazine on Trump’s deliberate dismantling of America’s War on Cancer

Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.
Guest Editorial

Curing cancer or curbing immigration: A question of national morality and priority

In December 1971, President Richard Nixon signed the National Cancer Act and declared a “War on Cancer.” In the past 54 years, the U.S. has invested $180 billion nominally, or approximately $322 billion when adjusted for inflation, in cancer research. This investment has paid dividends with more than 100 anticancer drugs brought to market in half a century—virtually all traceable to National Cancer Institute funding. 
By Paul W. Thurman
Byline
Matthew Bin Han Ong
Matthew Bin Han Ong
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account